Editorial
The role of Piccolo in cancer treatment: relationship with EGFR and related therapies, and a marker for new targeted therapies
Abstract
The use of high-throughput technologies becomes more and more relevant every day. Indeed, whole-genome and whole-exome sequencing represent methodologies of particular interest in the discovery of new molecular markers involved in cancer development. In this way, Song and colleagues identified a series of genomic alterations playing a potential relevant role in esophageal squamous cell carcinoma (ESCC) (1).